| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BNP; NPPB |
| Entrez GeneID | 4879 |
| clone | 9H6B4 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to aa (Gly-Leu-Gln-Glu-Gln-Arg-Asn-His-Leu-Gln-Gly-Lys-Leu-Cys) of human BNP, conjugated to KLH. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是3篇与BNP抗体相关的文献概览：
1. **《Development of a novel monoclonal antibody-based assay for detection of plasma B-type natriuretic peptide》**
*作者：Schellenberger U, et al.*
**摘要**：该研究开发了一种针对BNP的新型单克隆抗体，用于高灵敏度检测血浆中的BNP水平。通过表位定位技术筛选出特异性抗体，优化后的检测方法在心力衰竭患者中表现出良好的诊断一致性，为临床检测提供新工具。
2. **《Standardization of BNP and NT-proBNP Immunoassays: A 2020 Update》**
*作者：Mair J, et al.*
**摘要**：本文综述了BNP和NT-proBNP检测的标准化问题，重点讨论了不同抗体对检测结果的影响。作者指出，抗体选择(如针对BNP活性区域或稳定片段)是导致检测差异的主要原因，并呼吁全球统一检测标准以提高结果可比性。
3. **《Point-of-care testing of BNP: Antibody selection and clinical validation in emergency settings》**
*作者：Apple FS, et al.*
**摘要**：研究评估了基于单克隆抗体的床旁BNP快速检测设备的性能。与实验室检测相比，该方法的抗体设计有效避免了BNP降解产物的交叉反应，在急诊室中能快速区分心源性与非心源性呼吸困难，缩短诊疗时间。
4. **《Interference of heterophilic antibodies in BNP immunoassays: Mechanisms and solutions》**
*作者：Emerson JF, et al.*
**摘要**：分析了异嗜性抗体对BNP免疫检测的干扰机制，发现约5%的异常结果与此相关。研究提出通过抗体工程改良(如添加阻断剂、使用重组Fab片段)可显著降低假阳性/阴性风险，提升检测准确性。
B-type natriuretic peptide (BNP) is a cardiac hormone primarily secreted by ventricular cardiomyocytes in response to myocardial stretch and pressure overload. It plays a critical role in regulating blood pressure, fluid balance, and cardiovascular homeostasis by promoting vasodilation, natriuresis, and diuresis. Elevated BNP levels are strongly associated with heart failure (HF), making it a key diagnostic and prognostic biomarker in cardiovascular diseases.
BNP antibodies are essential tools in immunoassays designed to detect and quantify BNP or its inactive precursor, NT-proBNP, in blood samples. These antibodies are typically monoclonal, targeting specific epitopes on the BNP molecule to ensure high specificity and sensitivity. Clinically, BNP antibody-based assays (e.g., ELISA, chemiluminescence) are widely used in emergency and outpatient settings to differentiate cardiac from non-cardiac causes of dyspnea, monitor HF therapy efficacy, and predict adverse outcomes.
Challenges in BNP measurement include its short plasma half-life, biological variability, and cross-reactivity with structurally similar peptides like ANP or CNP. Advances in antibody engineering, such as epitope mapping and affinity optimization, have improved assay precision. Research continues to explore novel applications, including point-of-care testing and personalized treatment strategies. Overall, BNP antibodies remain indispensable in bridging cardiac pathophysiology with clinical decision-making.
×
